Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer

Keyphrases

• Lung Cancer 100%
• Cost-effectiveness 100%
• Diagnostic Evaluation 100%
• Genomic Classifier 100%
• Invasive Procedures 60%
• Bronchoscopy 60%
• Quality-adjusted Life Years 60%
• Gene Expression 40%
• Lung 40%
• Diagnostic Accuracy 40%
• Intermediate Risk 40%
• Diagnostic Work-up 40%
• Incremental Cost-effectiveness Ratio 40%
• Airway Epithelial 40%
• Follow-up Protocol 20%
• Reimbursement 20%
• Adverse Event Rates 20%
• Test Performance 20%
• Claims Data 20%
• Lung Cancer Risk 20%
• Procedural Costs 20%
• Decision-analytic Model 20%
• Markov Model 20%
• Competing Strategy 20%
• Value Strategies 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Cancer 100%
• Adverse Event 25%